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1. Introduction 
Liver biopsy is considered the gold standart for the diagnosis of cirrhosis, it has important 
limitations ,such as being invasive,having the potential for complications and false-negative 
results or underestimating disease severity due to sampling error. 
Liver biopsy is recomended in patiens with abnormal liver tests,for evaluation of chronic 
hepatitis, of alcohol liver disease, icterus of unknown origin, hepatomegaly,splenomegaly, 
ascites, cholestatic liver disease, toxic liver damage,metabolic disorders.Liver biopsy has 
limitations including small but significant morbidity and mortality rates,inter- and intra-
observer variation in patology reporting. The most important contraindications of liver 
biopsy are trombopenia, abnormal parameters of hemocoagulation, important ascites, liver 
hemangioma and cysts, acute cholangitis, biliary obstruction ,severe obesity, respiratory 
insufficiency, heart failure,Chilaiditi´s sy, uncooperative patient.(1) 
Complication of liver biopsy and their incidence: 
Pain (0,056 -22%)-pleural, peritoneal, diaphragmatic 
Bleeding-intraperitoneal(0,03-0,7%). 
- intrahepatic or subcapsular ( 0,059-23%) 
- hemobilia(0,059-0,2%) 
Biliary peritonitis(0,03-0,22%) 
Bacteriemia 
Sepsis(0,088 %) and liver absces 
Pneumothorax or pleural effusion (0,08-0,28%) 
Hemothorax (0,18-0,49%) 
Arteriovenous fistula (5,4%) 
Subcutaneous emphysema(0,014%) 
Reaction to anaestetic (0,029 %) 
Beakage of needle (0,02-0,059%) 
Biopsy of other organs: 
- lungs (0,001-0,014%). 
- gallbladder(0,034-0,117%), 
- kidney ( 0.029-0,096%) 
- colon (0.0038-0,044%) 
Death (0,0088-0,3%) 
Noninvasive methods of investigation of liver offer an atractive alternative to the liver 
biopsy, as they are less invasive than liver biopsy,repeatable. 
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Noninvasive approaches to assess histology in liver disease include clinical symptoms and 
signes, routine laboratory tests, serum markers of fibrosis and inflammation, quantitative 
assay of liver function and radiologic imaging methods.None of these tests or markers alone 
is accurate or reliable in predicting histology, in particular, liver fibrosis. 
An ideal noninvasive ,diagnostic test should be simple, readily available, inexpensive and 
accurate. 
2. Serum tests 
Serum tests are used for assessment of steatosis, hepatitis, cirrhosis, metabolic and 
autoimmune disorders for prediction of liver fibrosis. 
The group of routine tests includes liver enzymes- ALT, AST, ALP, GMT, level of bilirubin, 
platelets count, markers of infectious diseases, autoantibodies. 
Results of serum tests and derived mathematical models are always compared with 
histological findings. 
2.1 Markers of liver fibrosis 
Markers of the I st class, non-routine, are based on knowledge about fibrogenesis, they are 
components of extracellular matrix, which are overproduced by activated stellate cells. 
2.1.1 Non-routine markers 
Hyaluronic acid 
Hyaluronic acid (HA) concentrations have been shown to be higher in cirrhotic and fibrotic 
patients, sensitivity is 88 %, specificity 78% for cirrhosis. 
Most of hyaluronic acid in the blood is produced in the stellatae cells of the liver and is also 
cleared by the liver. Only small fraction of HA is eliminated via the kidneys and spleen. It is 
extracted from sinusoidal endothelial cells within 2-9 minutes. Its concentration in a normal 
liver tissue is low, but in fibrotic liver is 2 to10-fold increased.(2) 
HA serum concentrations rise significantly in case of cirrhosis. The cutoff is 60g/L. 
HA is not suggested to replace liver biopsy, but is useful for long-term monitoring of 
disease progression. 
Non- routine tests,which reflect fibrosis ,are extracellular matrix remodeling markers: 
amino-terminal propeptide of type III collagen(PIIIP),matrix metalloproteinase(MMP),tissue 
inhibitor of matrix metalloproteinase(TIMP),type IV collagen(CL-4).Markers are used alone 
or in combination with serum chemistries. 
Index of PIIIP/MMP-1 significantly correlates with fibrosis score and is considered better 
than hyaluronic acid and TIMP-1. 
Laminin 
Laminin -a major,noncollagenous,high mollecular-mass glycoprotein of basement 
membranes, increases in fibrotic liver. Increases in laminin concentration are positively 
correlated with the extent of fibrotic transition of the liver. 
Discrimination between fibrotic and cirrhotic stages of chronic liver diseases by means of 
laminin assay is better than the aminoterminal propeptide of type III procollagen.The 
increase of laminin is relatively independent of etiology of the disease(3) 
YKL-40 
YKL-40 can be used for diagnosing liver fibrosis,mild stage of fibrosis(value < 186,4), severe 
stage of fibrosis(186,4 < value < 284,8) and F4 (284,8 < value).(3) 
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YKL-40 is thought to contribute to tissue remodeling or degradation of the extracellular 
matrix.(4) 
Alpha-2-macroglobulin 
Alpha-2-macroglobulin (A2M) is a proteinase inhibitor and acute–phase protein.Cells 
synthetising A2M are hepatocytes, activated Ito cells and granuloma cells.Fibrosis is 
associated with an increase of A2M,which is considered very informative marker.A2M is 
included in Fibrotest,Actitest, PGAA index,Patel score,Fibrometer, Hepascore. 
Amino-terminal propeptide of type III collagen 
Amino-terminal propeptide of type III collagen(PIIIP) is marker of deposition rate of type III 
collagen. The serum concentration of PIIINP reflects the turnover of type IIIcollagen. 
Matrix metalloproteinase(MMP) 
Changes of MMP reflect „pathologic“ matrix degradation in liver. The most important 
enzymes are MMP -2(also called gelatinase A or 72-kDa type IV collagenase) and MMP-
9(gelatinase B or 92-kDa type IV collagenase), which reflects type IV collagen. Markedly 
increased expression of MMP-2 is characteristic of cirrhosis.(5) 
Tissue inhibitor of matrix metalloproteinase(TIMP) 
Significant increases of TIMP 1 and TIMP 2 have been observed in chronic liver disease at 
any stage of the fibrotic process.(5) 
Type IV collagen(CL-4) 
CL-4 is a sensitive marker for active fibrosis and the elevation of serum type IV-collagen 
level reflects the enhancement of type IV-collagen synthesis and deposition in the liver 
tissue at the stage of active fibrosis in liver disease. 
Elevated serum amino-terminal propeptide of type III collagen ,prolylhydroxylase(PH), 
collagen type IV and matrix metalloproteinase-1 were seen in cirrhosis of various cause, 
laminin and CL-IV in alcoholic hepatitis, hyaluronic acid,tissue inhibitor of 
metalloproteinase TIMP-1and TIMP-2, in chronic hepatitis. Serum CL-IV, MMP-2 and 
TIMP-1(but not laminin, MMP-1or MMP-3) were elevated in hereditary hemochromatosis, 
and only CL-IV and MMP -2 correlated with severity of hepatic fibrosis. 
Prolylhydroxylase is marker of collagen synthesis, reflects the grade of fibrosis. 
Type VI collagen 
Type VI collagen is a minor but essential matrix component in the liver.Type VI collagen 
gene expression, together with other connective tissue components, including type I 
collagen, is activated in the early stages of the fibrotic process. Type VI collagen 
accumulation may contribute to the distorted architecture and functional impairment of the 
liver in hepatic fibrosis.(6) 
Tenascin 
is the extracellular matrix glycoprotein .A significant correlation was observed between the 
serum tenascin levels and serum levels of various extracellular matrix proteins such as type 
III procollagen N –aminoterminal peptide(PIIIP), laminin and the 7Sdomain of type IV 
collagen. A strong positive correlation was observed between the serum tenascin levels and 
histological findings,particullarly in the degree of hepatic fibrosis (7) 
Undulin 
Undulin is a constituent of the hepatic extracellular matrix of normal human liver. Undulin 
is distributed as densely packed fibers in portal tract stroma, and as fine fibers along 
sinusoids,and around central veins.Undulin ribonucleic acid expression is low in normal 
liver,and confined to mesenchymal cells of portal tract stroma, vessel walls and 
perisinusoidal space. In fibrotic liver , undulin deposition and gene expression are enhanced 
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in fibrotic stroma and area of fibrogenesis identified by the presence of active septa and 
inflammatory infiltrate.Undulin participates in rearrangement of connective tissue occuring 
in hepatic fibrosis.(8) 
Fibronectin 
Fibronectin plays a role in liver fibrosis, which was studied in Egyptian patiens with chronic 
HCV infection.The efficiency of fibronectin for disciminating patiens with liver fibrosis from 
those with non fibrosis livers was 75%.Serum fibronectin can differentiate HCV infected 
patiens with liver fibrosis from patiens with non fibrosis(9). 
 
Marker SerumUrineBiopsyMethod 
Clinical 
application 
Prolylhdroxylase + - + REA, RIA (+) 
Monoaminoxidase + - (+) Enzymatic - 
Lysyloxidase + - + RIA - 
Lysylhydroxylase + - - RIA - 
Galaktosylhydroxylysylglukosyltransferase + - + RIA - 
Collagenpeptidase + - + Enzymatic - 
N-acetyl-beta-D-glukosaminidase + + + Enzymatic (+) 
Collagen typ I   
N-terminal propeptide (PINP) + - + ELISA - 
C-terminal propeptide (PICP) + - + RIA - 
Collagen typ III   
Intact procollagen + - -  
N-terminal propeptide (PIIINP)   
Globular domain of propeptide (Col-1) + - - RIA + 
Collagen typ IV   
NC1-fragment [C-terminal] (PIVP) + + - ELISA, RIA (+) 
7S domain (7S collagen) + + - RIA (+) 
Collagen typ VI + + + RIA - 
Laminin, P1-fragment + - - RIA, EIA (+) 
Undulin + - - EIA - 
Vitronectin + - - EIA - 
Tenascin + - - ELISA - 
YKL-40 + - + RIA, ELISA (+) 
(pro) MMP-2 + - - ELISA (+) 
TIMP-1, TIMP-Ď + - - ELISA (+) 
Hyaluronic acid + - - 
RLA, 
ELISA
++ 
Fig. 1. Non-routine tests of liver fibrosis (30) 
2.1.2 Routine tests 
ALT,AST have been the most often used enzymes indicating hepatocellular damage.Activity 
of ALT is higher than AST,the exception is in alcohol liver disease and Rey´s syndrom. 
Aminotransferases are elevated 3-20 fold in acute and chronic hepatitis, toxic liver 
damage.Elevation less than3-fold is in steatosis. nonalcoholic steatohepatitis, chronic 
hepatitis.Mild elevation is in cholestatic liver disease, liver cirrhosis. 
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AST/ALT ratio(de Ritis index) is usefull in alcohol liver disease,because AST/ALT > 2 is 
specific test for alcohol liver disease. AST/ALT < 1 is typical for viral hepatitis, but increase 
> 1 indicates progresssion to cirrhosis.  
Single markers often correlate with fibrosis in large groups of patients, but do not 
sufficiently assess the amount of fibrosis in a single individual,especially in longitudinal use 
over time. 
Haptoglobin 
is a plasma glycoprotein which specially binds hemoglobin and is synthesized in the 
liver.Haptoglobin is the acute-phase protein and is strongly and negatively associated with 
fibrosis 
Apolipoprotein A1 
is synthesized by the liver and is responsible for cholesterol transport. It is included in 
extracellular matrix and its level is decreased at increasing stages of fibrosis. 
Total bilirubin 
is formed during decomposition of hemoglobin in the cells of the reticuloendothelial system 
especially in the spleen and Kupfer cells of the liver. Increase in its level suggests 
hepatocellular failure,except case of hemolysis. 
Apolipoprotein A1, haptoglobin,bilirubin are components of mathematical models for prediction of 
liver fibrosis. 
Forns index was developed to discriminate patiens with and without significant fibrosis 
with a noninvasive method.The cohort included 476 consecutive untreated patiens with 
chronic hepatitis C who underwent a liver biopsy.The study was designed to assess the 
accuracy of noninvasive method aimed to discriminate between patiens with and without 
significant liver fibrosis(stages 2-4 versus 0-1) The model consisted of combination of 4 
variables identified by comparative analysis of patients with and without significant 
fibrosis: age,gamaglutamyltransferase, platelet count,cholesterol level(10). With these 
variables were constructed a simple score adressed to select patients at very low risk of 
having significant fibrosis. 
7,811-3,131.ln(platelet count)+0,781.ln(GMT)+3,467.ln(age)-0,014.(cholesterol). 
Two cutoff values were chosen to identify absence (less than 4,21)and presence (greater 
than6,9) of significant fibrosis.A score below 4,2 identified patiens at very low risk of having 
significant fibrosis with a96% certainty. 
The age as a marker of liver fibrosis was used, because fibrosis progression is time 
dependent. The duration of HCV infection would be a more precise indicator of fibrosis 
than age. A low platelet count is a marker of severe fibrosis. Thrombocytopenia in patiens 
with advanced liver disease seems to be related to the development of portal hypertension 
and the decreased production of thrombopoetin. In this study ,increased GGT was an 
independent predictor of bile duct damage, because HCV infection frequently cause bile 
duct damage and steatosis. Patiens with bile duct lesions have significantly higher fibrosis 
score. 
Wai et al. considered platelet count and AST level as the most important predictors of 
fibrosis and analyse the relationship between these two factors and the stage of hepatic 
fibrosis.(11) 
Regression formula for prediction of signifiant fibrosis: 
 Risk score = 2.318 + 0,274.ln(AST level[/ULN])-0,375.ln (platelet count [109/L]) 
Regression formula for prediction of cirrhosis:  
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Risk score=2,411+ 0,100.ln(AST level[/ULN])-0,436.ln(platelet count [109/L]) 
APRI = 
9
AST(/ULN)
100
PLT(10 /L)
  
The APRI was accurate in predicting both fibrosis and cirrhosis,with area under ROC of 0,8 
and 0,898 in the training set, and 0,88 and 0,94 in the validations set. 
The study of Wai included 270 patients.APRI predictive model consists of objective and 
readily available laboratory variables. The finding of decreased platelet count and increased 
AST level with progression of liver fibrosis has been reported in many studies.With 
increasing fibrosis and worsering portal hypertension, there are increased sequestration and 
destruction of platelets in the enlarging spleen.Progression of liver fibrosis may reduce the 
clearance of AST, leading to increased serum AST levels.The APRI was accurate in 
predicting both signifiant fibrosis and cirrhosis.with area under ROC of 0,80 and 0,89 in the 
training set,and 0,88 and 0,94 in the validation set. Although was not definied one single 
cut-off value to predict the only study endpoint, using values below the lower cut-off level 
and above the higher cut-off level, a prediction of absence of cirrhosis could be made in 81 % 
of patients.Similary, a prediction of absence or presence of significant fibrosis could be made 
in 51 % of patiens.The major advantage of the APRI is its simplicity. APRI can be 
determined in the clinic or bedside without the help of a calculator. 
FibroTest 
is a patented biomarker test that uses the results of six blood serum tests to generate a score 
that is correlated with the degree of liver damage in people with variety of liver disease. 
FibroTest has the same prognostic value as a liver biopsy. 
FibroTest was presented in 2002. Study included 125 patients with chronic hepatitis 
C.Serum tests were taken at time of biopsy.The score was computed from age, sex and 
serum alpha2 macroglobulin,bilirubin, gamaglutamyltransferase activity, apolipoprotein A1 
and haptoglobin.(12) 
The equation for calculating FibroTest is 
z = 4,467 x log10 [alpha2macroglobulin(g/L)] - 1,357 x log 10 [haptoglobin(g/L)] + 
 1,017 x log10[GMT(IU/L)] + 0,0281 x [age(years)] + 1,737 x log10[bilirubin(mol/L)] -
1,184 x [apolipoprotein A1(g/L)] + 0,301 x sex(female=0,male=1) - 5,54 
At the recommended cutoff values, the negative predictive value of a FibroTest score < 0,1 
for the presence of fibrosis stages F2 toF4 was 85%, the positive predictive value of a score 
>0,6 was78% and a score of 0,6 gave a likehood ration of 6,4. 
The laboratory or physician connects to the BioPredictive website for calculation of the test 
results and prints the results sheet, which is available immediately and is accompanied by 
an interpretation aid and precautions for use. 
In clinical practice it has been suggested that the FibroTest score might be applied to patiens 
who either have contraindications or risk liver biopsy for the management of their 
HCV.FibroTest score could not accurately predict either the presence or absence of 
significant fibrosis and cold not reliably be used to reduce the need for liver biopsy. 
Other tests derived from FibroTest are:  
ActiTest-diagnostic for necrotico-inflammatory hepatitis 
SteatoTest –diagnostic for liver steatosis 
NashTest-diagnostic for NASH inflammation 
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AshTest diagnostic for Alcoholic liver disease inflammation 
FibroTest is independent of ethnic origin,sex,genotypes,viral load,transaminases or the 
presence of comorbidities. The test has been validated for the general population,including 
children,patiens with renal insufficiency, hemophiliacs, patiens with chronic inflammatory 
disease. 
The test is not applicable in 1 to5% of cases, in patiens with acute viral hepatitis 
A,B,C,D,E,drug-induced hepatitis, extrahepatic cholestasis, severe hemolysis, Gilbert´s 
syndrome with high unconjugated hyperbilirubinemia,acute inflammatory syndrome. 
FibroTest has comparable diagnostic value as 25 mm biopsy,while being noninvasive and 
easily repeatable. 
ActiTest includes parameters of FibroTest plus the level of ALT.  
SteatoTest was constructed using a combination of the 6 components of FibroTest-ActiTest 
plus body mass index,serum cholesterol,triglycerides and glucose adjusted for age and 
gender.(13)  
NashTest was developed using patented algorithms combining 13 parameters: 
age,sex,heigh,weight,and serum levels of triglycerides,cholesterol, A2M,apolipoproteinA1, 
haptoglobin, GMT, ALT, AST, total bilirubin.(14) 
AshTest is calculated using A2M, haptoglobin, apolipoprotein A1, total bilirubin, GMT, ALT 
and AST,with parameters adjusted for patienst´s gender and age. 
FibroMAX  is used for monitoring liver health in patients with viral, metabolic or alcoholic 
hepatitis when symptoms or risk factors are difficult to interpret. 
FibroMAX is a combination of five algorithm tests – FibroTest, ActiTest, 
SteatoTest,NashTest, and AshTest. FibroMAX uses a unique combination of serum marker 
tests and other patient ´s data including age, gender, weight and height. The test results and 
patient´s data are entered into patented algorithms, which accurately determine the level of 
liver disease. Serum markers measured by FibroMax include Alpha 2-macroglobulin, 
Haptoglobin, Apolipoprotein A1, Total bilirubin, Gamma Glutamyl Transpeptidase (GGT), 
Alanine Amino Transferase (ALT), Aspartate aminotransferase (AST), Fasting Glucose, 
Triglycerides, total cholesterol. The serum marker levels are analysed using BioPredictive 
algorithms to create the FibroMAX Test Report. 
As FibroMax  includes a Fasting Glucose test, fasting is required before sample collection.  
Fib-4 
combines standard biochemical tests-platelets,ALT,AST and age.The Fib 4 test was studied 
in cohort of 847 HCV patiens, also was performed liver biopsy and FibroTest. An Fib4 index 
value higher than 3,25 had a positive predictive value to confirm the existence of signifiant 
fibrosis F3-F4 of 82,1% with with a specificity of 98,2%. An Fib -4 index lower than 1,45 had 
a negative predictive value of 94,7 % to exclude severe fibrosis with a sensitivity of 74,3%. 
The FIB-4 index was strongly correlated to the FibroTest results for a score <1.45 or >3.25. 
For values outside 1,45-3,25 the Fib-4 index is a simple,accurate and inexpensive 
method.(15) 
Hepascore 
is based on serum levels of alpha2macroglobulin, hyaluronic acid, 
gammaglutamyltransferase, total bilirubin, along with age and sex.(16) 
The logistic regression model of: 
y = exp [-4,185818-(0,0249 x age) + (0,7464 x sex) + (1,0039xA2M) +  
(0,032 x hyaluronic acid) + (0,0691 x bilirubin) -(0,0012x GGT)] 
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The Hepascore was calculated from the following equation: 
y/1+y 
Hepascore higher than 0,5 is 67 % sensitive and 92 % specific for the presence of significant 
fibrosis, score lower than 0,5 is 88% sensitive and 74 % specific for excluding advanced fibrosis. 
The cutoff point of 0,84 was applied for detection of cirrhosis. 
Hepascore has been shown to be accurate as liver biopsy in patiens with hepatitis C virus 
infection. Hepascore is applicable to the assessment of fibrosis in alcoholic and non-alcoholic 
fatty liver disease. Hepascore will allow more frequent monitoring to detect progression of 
liver disease and also response to therapy. 
PGA  
is a simple biological index combining a specific test for severe liver disease-protrombin 
time, a sensitive test of alcoholic liver disease-serum gammaglutamyl transpeptidase,and a 
test for liver fibrosis-serum apolipoprotein A1.The test was evaluated in a training sample of 
333 drinkers and validated in 291 other drinkers.All patiens underwent a liver biopsy.The 
PGA index varied from 0 to12. When PGA was less than or equal to 2, the probability of 
cirrhosis was 0% and the probability of normal liver or minimal changes 83%.When PGA 
was greater than or equal to 9, the probability of normal liver or minimal changes was 0% 
and the probability of cirrhosis 86 %. 
The diagnostic accuracy of this index was later improved by the addition of 
alpha2macroglobulin.(17) 
PGAA 
includes protrombin time,gamaglumatyltranspeptidase, apolipoprotein A 1 and 
alpha2macroglobulin. 
Fibrometer 
generates a score of fibrosis with an equivalence in F Metavir stage. 
FibroMeters are blood tests for liver fibrosis with several specificities:two main diagnostic 
targets(fibrosis stages and area of fibrosis),adaptation to specific causes, and results 
confirmed by an expert system. 
FibroMeters comprise six different tests: on effort paging and on effort quantitation of liver 
fibrosis in each of the free main cause of chronic liver disease- chronic viral hepatitis, 
alcoholic liver disease and nonalcoholic fatty liver disease. 
There are 6 different main Fibrometers. 
FibroMeter V(Band C virus and co-infection HCV/HIV) 
score of fibrosis: age,gender,alpha2macroglobulin, prothrombin time, platelets,AST,urea, 
GGT,ALT 
score of cirrhosis: age, gender,alpha2macroglobulin,prothrombin time, platelets,AST,urea, 
GGT,ALT 
activity: alpha2macroglobulin, prothrombin time,platelets, ALT 
Fibrometer A(alcohol) 
score of fibrosis: age, gender,alpha2macroglobulin, hyaluronic acid,prothrombin time 
percentage of fibrosis: alpha2macroglobulin,hyaluronic acid, platelets, hyaluronic acid 
FibroMeter S(metabolic steatosis) 
score of fibrosis: age,grade, patiens weight, platelets, AST,ALT,ferritin,glucose 
percentage of fibrosis: hyaluronic acid, prothrombin time, platelets, AST, ALT, glucose 
FIBROspect II was first described for hepatitis C patients in 2004. Fibrospect uses three 
serum markers, alpha 2 macroglobulin, hyaluronic acid and Tissue inhibitor of matrix 
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metalloproteinase, to calculate a score. When applied to 696 patients with hepatitis C, a 
score <0.36 excluded significant fibrosis with a negative predictive value of 76% and a score 
>0.36 detected significant fibrosis with a positive predictive value of 74%. 
Fortunato 
The test is based on concenrations of six biochemical markers- fibronectin, prothrombin, 
pseudocholinesterase, ALT, manganese superoxid dismutase, N- acetyl- beta- 
glucosaminidase.(18) 
Following equation was developed  
discriminant score = PCHE(kat/L) x 0,00011 + fibronectin(mg/L) x 0,039 +  
ln prothrombin activity(%) x 3,51 + ln ALT(kat/L) x 0,49-ln beta NAG(kat/L) x 0,51 – 
 ln MnSOD(kat/L) x 1,29 – 9,41 
Fortunato et al. studied two cohorts-54 patients with chronic hepatitis and 49 patients with 
cirrhosis.All patiens underwent percutaneous liver biopsyand laboratory tests. 
The cutoff value was -0,22 (less than -0,22 indicated cirrhosis, greater than -0,22 indicated 
chronic hepatitis). 
Prothrombin activity and PCHE are markers of liver protein synthetic activity, which is 
gradually impaired during the cirrhotic evolution of chronic hepatitis. 
b-NAG and fibronectin are markers of fibrosis . The increase in serum b-NAG activity in 
cirrhotic patients is attributable to the increased accumulation of collagen typical of the 
disease. b-NAG is known to be important for the collagen pathways . By contrast, the 
reduction of circulating fibronectin in cirrhotic patients is likely related to the impaired 
protein synthesis that occurs in cirrhotic liver . Mn-SOD is located mainly in the 
mitochondrial matrix, a site of reactive oxygen species production; it is involved in the 
antioxidative pathways of human cells . 
Mn-SOD mRNA concentrations in peripheral blood mononuclear cells and serum Mn-SOD 
concentrations are higher in patients with hepatitis C viral infections than inhealthy 
controls. Serum ALT could be considered a signal of liver cytolysis, which differs in chronic 
hepatitis and cirrhosis. 
Fibronectin, ALT, PCHE, prothrombin activity, Mn-SOD, and b-NAG blood concentrations 
are easily and rapidly analyzed 
Patel 
developed the model using levels of extracellular matrix remodeling proteins. Study 
included 294 patients with chronic hepatitis C and was validated in an external cohort of 402 
patients. The aim of this study was to evaluate the diagnostic accuracy of a panel of these 
markers in chronic hepatitis C patients develop a predictive algorithm that differentiates 
no/mild (METAVIR F0-F1) from moderate/severe ( F2-F4) fibrosis,and valid the model in 
external cohort.(19) 
Hyaluronic acid, TIMP -1 and alpha2macroglobulin were selected as having the best 
accuracy for F2-F4 fibrosis. At an index cut-off >0.36 and prevalence for F2–F4 of 52%, 
results in all 696 patients indicated positive and negative predictive values of 74.3 and 75.8% 
with an accuracy of 75%. 
Pohl score 
 Positive : AAR ≥1 and platelet count <150 ×109/L 
 AAR = AST/ALT 
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Cirrhosis disciminant score 
The CDS was developed by Bonacini.The CDS includes platelets.ALT/AST ratio, and 
prothrombin time. The CDS of 8 or higher had a sensitivity of 46% and specificity of 98% for 
diagnosis of histological fibrosis scores of 3 or 4.(20,21) 
 
CDS 
Platelet count (×109/L): >340 = 0; 280–339 = 1; 220–279= 2;  
160–219 = 3; 100–159 = 4;  
40–99 = 5; <40 = 6 
  ALT/AST ratio: >1.7 = 0; 1.2–1.7 = 1; 0.6–1.19 = 2;<0.6 = 3 
  INR: <1.1 = 0; 1.1–1.4 = 1; >1.4 = 2 
  CDS is the sum of the above (possible value 0–11). 
 
AP index 
Age (years): <30 = 0; 30–39 = 1; 40–49 = 2; 50–59= 3; 
 60–69 = 4; ≥70 = 5 
  
Platelet count (×109/L): ≥225 = 0; 200–224 = 1; 175–199= 2;  
150–174 = 3; 125–149 = 4; <125 = 5 
  
AP index is the sum of the above (possible value 0–10). 
AP index of 6 or higher is significant for advanced fibrosis 
Enhanced liver fibrosis (ELF) test 
originaly combined age and three markers of liver fibrosis-hyaluronic acid, aminoterminal 
propeptide of type III collagen and tissue inhibitor of matrix metalloproteinase 1.The test 
was investigated on international multicenter cohort study. Subsequently the ELF team have 
established that Age could be omitted from the algorithm to generate the Enhanced Liver 
Fibrosis test or ELF Test. Performance was excellent for alcoholic liver disease and non 
alcoholic fatty liver disease.(22) 
Combinations of serum markers for fibrosis calculated by algorithms, which give a 
discriminant score for fibrosis, represent a new group of liver function tests, which 
provide an alternative to an invasive liver biopsy. Providing they are properly validated, 
scores generated from combinations of serum tests represent a method for medical 
laboratory science to add value to laboratory reports. Clinicians must interpret 
conventional liver function tests carefully with only the individual reference ranges 
customarily provided by the laboratory for guidance. Experienced clinicians learn to 
make judgements and interpretations of conventional liver function tests, which are well 
beyond the scope of the reference ranges, and often difficult for less experienced 
clinicians. An advantage of algorithm-based scores is that a properly validated score 
represents evidence-based medicine as it incorporates clinical experience in the 
presentation of the reset. 
ELFGA index  
Includes parameters: age, aminoterminal propeptide of type IIIcollagen, haptoglobin, tissue 
inhibitor of matrix metalloproteinase 1. 
FibroIndex 
combines aspartate aminotransferase(AST), platelet count and gamaglobulin measurements.  
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Koda et al developed the FibroIndex to predict significant fibrosis.The authors collected 
clinical data on 402 consecutive patiens with chronic HCV-liver biopsy and blood samples 
taken no more than three days before the biopsy. Patiens were excluded if they had HIV or 
hepatitis B co-infection,drank more than10g of alcohol per day,had other liver disease, 
previous interferon therapy, or clinical evidence of cirrhosis, such as gastroesophageal 
varices, ascites, or hepatic encephalopathy.The investigators used multivariate logistic 
regression analysis to identify independent risk factors for fibrosis.(24) 
FibroIndex = 1,738 - 0,064(plateles[ x 104/mm3]) + 0,005(AST[IU/L]) +  
0,463(gamma globulin[g/dl]) 
The index was tested in two validation sets.The investigators found that the areas under the 
receiver operating characteristic curves of the FibroIndex for predicting significant fibrosis 
were 0,83 and 0,82 for the validation set.The predictive value of the FibroIndex was better 
than either the Forns index or the aminotransferase to platelet ratio index.  
Fibrosis Probability Index 
FPI includes age, AST, past alcohol intake,cholesterol insulin rezistence,which was 
calculated from fasting serum insulin and plasma glucose determinations using the 
homeostasis model assessment(HOMA-IR) method:  
fasting insulin(mU/mL) x plasma glucose (mmol/L). 
An FPI was constructed using these independent predictors to determine the probability 
(0,0-1,0) of patient having signifiant fibrosis. 
SHASTA index 
Kelleher et al.developed a biomarker assay in a cohort of 95 HIV/HCV co-infected patients 
utilising Serum Hyaluronic acid, AST and Albumin (SHASTA). As with other biomarker 
assays, optimal results were noted in the extreme categories. Using a cutoff of 0.8 resulted in 
a specificity of 100% and a positive predictive value of 100% but this applied to less than 5% 
of patients. At the other end of the spectrum a cutoff of <0.30 was associated with a 
sensitivity of >88% and a negative predictive value of >94%. Overall 42% of patients could 
be correctly classified at either extreme but 58% would not be classifiable with scores 
between 0.3 and 0.8. The SHASTA index in HIV/HCV has similar accuracy to FibroTest and 
in this study performed significantly better than the APRI test(25) 
The Sequential Algorithm for Fibrosis Evaluation  
(SAFE) combines the APRI and Fibrotest-Fibrosure tests . In a large multicenter study 
validating this algorithm to detect significant fibrosis (stage F2 or greater by the F0–F4 
METAVIR scoring system), its accuracy was 90.1%, the area under the receiver operating 
characteristic curve was 0.89 (95% CI 0.87–0.90), and it reduced the number of liver biopsies 
needed by 46.5%. When the algorithm was used to detect cirrhosis, its accuracy was 92.5%, 
the area under the curve was 0.92 (95% CI 0.89–0.94), and it reduced the number of liver 
biopsies needed by 81.5%.  
FibroFast 
A simple noninvasive score (FibroFast) was developed and evaluated on the basis of several 
simple blood biomarkers (ALT:AST ratio, albumin, alcaline phosphatase, and platelets 
count) that can be easily used by clinicians to predict severe fibrosis or cirrhosis in patients 
with chronic HCV infection . The validation of 1,067 cases from several international centers 
(Egypt, Italy, Brazil, Romania, and UAE) showed that the sensitivity of FibroFast was 61.5%, 
specificity 81.1%, positive predictive value 59%, and negative predictive value 82.6%. New 
cut-off scores of FibroFast were developed that allow the diagnosis of cirrhosis (F4) and F0–
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F3 with the highest possible accuracy (>95%). FibroFast with the new two cut-off scores 
could be an alternative to liver biopsy in about one-third of the patients, with sensitivity 
95% and specificity 95% . 
 
Index, score Parameters Disease 
Senzitivity 
% 
Specificity 
% 
PGAA 
Prothrombin time, GGT, 
apolipoprotein A1, alfa-2-
macroglobulin 
Alcohol 79 89 
Bonacini 
Ratio ALT/AST, INR, platelet 
count 
HCV 46 98 
De Ritis Ratio AST/ALT HCV 53 100 
PGA 
Prothrombin time, GGT, 
apolipoprotein A1 
Mixed 91 81 
Fortunato 
Fibronectin, prothrombin time, 
PCHE, ALT, Mn-SOD, beta-
NAG 
HCV  94 
Fibrotest 
Haptoglobin, alfa-2-
macroglobulin, apolipoprotein, 
A1, GGT, bilirubin 
HCV, 
HBV 
75 85 
Pohl Ratio AST/ALT, platelet count HCV 41 99 
Actitest Fibrotest + ALT HCV   
Forns 
Age, platelet count, GGT, 
cholesterol 
HCV 94 51 
WAI (APRI) AST, ALP, platelet count HCV 89 75 
Rosenberg  
ELF-test 
PIIINP, hyaluronic acid, TIMP-
1 
Mixed 90 41 
Patel 
Hyaluronic acid, TIMP-1, alfa-
2-macroglobulin 
HCV 77 73 
Sud (fibrosis 
probability 
index, FPI) 
Age, AST, cholesterol, insulin 
resistence (HOMA), past 
alcohol intake 
HCV 96 44 
Leroy PIIINP, MMP-1 HCV 60 92 
Fibrometer 
Platelet count, prothrombin 
index, AST, alfa-2-
macroglobulin, hyaluronic 
acid, urea, age 
Mixed 81 84 
Hepascore 
Bilirubin, GGT, alfa-2-
macroglobulin, hyaluronic 
acid, age, gender 
HCV 63 89 
Testa 
Ratio platelet count/spleen 
diameter 
HCV 78 79 
FIB-4 Platelet count, AST, ALT, age 
HCV, 
HIV 
70 74 
Fig. 2. Routine tests of liver fibrosis (30) 
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3. Imaging methods 
3.1 Ultrasound 
Ultrasound has been used for noninvasive investigation of liver, for detection of focal 
lesions, assessment the degree of liver fibrosis, description of trombosis of portal vein. 
Ultrasonographic parameters may represent an alternative to serum markers for the 
noninvasive assessment of liver disease severity and stage by finding signs of portal 
hypertension as splenomegaly, ascites, or a patent umbilical vein, and by examining the 
size, nodular liver surface, echogenicity and echotexture of the liver parenchyma.   
The sensitivity of liver ultrasound scans in the diagnosis of fatty liver is almost 100 %. The 
correlation of fatty liver in ultrasound scans and liver biopsy tissue examination is 73.6 %. 
So, the degree of fatty infiltration observed in ultrasound scans is significantly correlated 
with degree of fatty accumulation of liver. 
Some studies have shown an association between ultrasonography score and detection of 
cirrhosis with sensitivities ranging 87,5% to 100% and specificities ranging from 81,5% to 
93,5%. 
Contrast-enhanced ultrasound (CEUS) is the application of ultrasound contrast mediumto 
traditional medical sonography. Ultrasound contrast agents rely on the different ways in 
which sound waves are reflected from interfaces between substances. This may be the 
surface of a small air bubble or a more complex structure. Commercially available contrast 
media are gas-filled   microbubbles that are administered intravenously to the systemic 
circulation. Microbubbles have a high degree of echogenicity, which is the ability of an 
object to reflect the ultrasound waves. The echogenicity difference between the gas in the 
microbubbles and the soft tissue surroundings of the body is immense. Thus, ultrasonic 
imaging using microbubble contrast agents enhances the ultrasound  backscatter, or 
reflection of the ultrasound waves, to produce a unique sonogramwith increased contrast 
due to the high echogenicity difference. Contrast-enhanced ultrasound can be used to image 
blood perfusion  in organs, measure blood flow rate in the heart and other organs, and has 
other applications as well.(26) 
Vyas found that portal venous blood flow(PVBF), portal flow velocity(PFV) and gastric 
mucosal blood flow(GMBF) were all significantly slower in cirrhotic patiens and PVBF and 
PFV were lower in Child class B/C than class A. 
Schneider et al. found that Doppler ultrasound alone was unable to discriminate between 
degrees of fibrosis, but portal venous undulations could predict liver cirrhosis with 
increased sensitivity(76,5%).(27) 
Hirata et al. derived an arterio-portal(A/P)ratio by evaluating hepatic hemodynamics, 
which was higher in patients with cirrhosis compared with controls and demonstrated 
statistically significant differences in A/P ratio when comparing severe-to-mild or moderate 
fibrosis. 
Hepatic vein transit times(HVTT) is using an ultrasound microbubble contrast agent as a 
tracer and has been investigated for grading liver disease. 
Abbatista found that HVTT was significantly shorter in cirrhotic patients than in non -
cirrhotic patients and distinguished between these patients with high accuracy 
These results show that unenhanced Doppler ultrasound in not reliable in discrimination of 
varying degree of fibrosis, but that results can be improved with additional measurements 
such as heart pulsation at the liver surface and portal venous flow measurements. 
High-resolution ultrasound of liver surface(LSS) can be used for investigation of liver 
cirrhosis. Liver surface is studied at the left liver lobe and is scored as smooth, irregular, 
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nodular. The smooth liver surface excludes cirrhosis, in case of irregular surface the results 
are indeterminate, the diagnosis of cirrhosis is when the surface is nodular. 
The result can be improved with quantification,when the liver surface is semi-automatically 
measured. 
The combination of ultrasonography and laboratory tests can improved the discrimination 
of patients with severe fibrosis and cirrhosis. Festa et al. investigated the cohort of 1143 
patients with chronic hepatitis C, who underwent liver biopsy, laboratory tests and US. 
All indices had specificity rate of > or =90% in excluding bridging fibrosis/cirrhosis, 
whereas sensitivity was acceptable (51%) for only platelet counts <140 000/L. None of the 
ultrasonographic parameters singularly evaluated and reached an acceptable sensitivity 
rate. For ruling cirrhosis in or out, specificity rate was > or =82% for all tests, with the 
highest value reported by portal vein size. Low platelet counts plus nodular liver surface 
had the best sensitivity. 
Ratio platelet/spleen diameter can be also beneficial 
Acoustic radiation force impulse elastography 
ARFI imaging technology involves the mechanical excitation of tissue using short-duration 
acoustic pulses (push pulses) in a region of interest chosen by the examiner, producing shear 
waves that spread away from the region of interest, generating localized, micron-scale 
displacements in the tissue . Simultaneously, detection waves of lower intensity than that of 
the push pulse are generated. The push pulse uses a few hundred cycles and different 
voltage compared to the short cycle B-mode pulse. The moment of interaction between the 
shear waves and detection waves marks the period of time elapsed between the generating 
of shear waves and their entire crossing of the region of interest. By recording the shear 
wave front at several locations and correlating these measurements with the elapsed time, 
the shear wave velocity (m/s) can be quantified; generally, the stiffer a region in the tissue, 
the greater the shear wave velocity as it travels through this region. 
ARFI elastography has a good accuracy of diagnosis of liver fibrosis in chronic liver 
disease,might be available for the prediction of chronic liver disease related events such as 
hepatocellular carcinoma, esophageal varix.(28) 
3.2 Elastography 
Elastography is a noninvasive method measuring the mean stiffness of hepatic tissue ,a 
parameter, which correlates hihgly with liver fibrosis. 
Transient elastography -FibroScan, Echosens, France , is equipped with a probe consisting in 
an ultrasonic transducer mounted on the axis of the vibrator. The probe is placed between 
two ribs in intercostal positions (sixth-eight intercostal area) on the right lobe of liver.A 
region of the liver selected for the test must be free from blood vessels structures of greater 
than 5 mm in diameter and should be homogenous.The sensor is focused at the zone of 25-
65 mm from the surface of the skin. Vibrations of mild amplitude and low frequency are 
transmitted from the vibrator to the tissue by the transducer itself. This vibration induces an 
elastic shear wave , which propagates through the tissue. In the meantime, pulse-echo 
ultrasonic acquisitions are performed to follow the propagation of the shear wave and 
measure its velocity ,which is directly related to the tissue stiffness. The harder the tissue, 
the faster the shear wave propagates. After correct installation of the sensor,10 reliable 
measurements are taken and based on thein results, the software calculates the value of 
hepatic elasticity. The results are expressed in kilopascals(kPA) and median values are 
representative of liver stiffness.Following the previous studies TE was considered to exclude 
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cirrhosis at<12 kPa, indeterminate at 12-18 kPa, and to diagnose cirrhosis if >18kPa. 
FibroScan provides accurate prediction of hepatic fibrosis in patiens with chronic viral 
hepatitis,chronic cholestatic disease, provides accurate prediction of cirrhosis and its 
severity in patiens with chronic liver disease. 
 
 
Fig. 3. Fibroscan (31) 
3.3 Magnetic resonance imaging 
Magnetic resonance imaging has been used for description of focal lesions- hemangiomas, 
liver tumors, malignant and also liver adenomas, focal nodular hyperplasia, for evaluation 
of liver fibrosis, for description of portal vein as MR splenoportography. 
In MRI investigation is also often necessary using of contrast medium. Sensitivity of MRI for 
detection of liver focal lesions is 80-100%, sensitivity is higher than sensitivity of US or CT, 
specificity is more than 96%. 
As contrast medium is often used gadollinium, superparamagnetic iron oxide(SPIO). 
Sequential administration of gadolinium and SPIO is used for investigation of liver 
fibrosis.Although SPIO-based images were highly accurate(85%) for detectiong fibrosis 
compared with histopatological features, the combination of gadolinium-based and SPIO 
contrast agents yielded even greater accuracy (93%) overall.  
Diffusion weighted magnetic resonance imaging (DWMRI) has been widely used in brain 
imaging for the evaluation of acute ischemic stroke. With the advent of the echo-planar MRI 
technique, it became possible to be applied in the abdomen for the characterization of focal 
hepatic lesions. Recently, using DWMRI to measure the apparent diffusion coefficient 
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(ADC) of water, a parameter that is dependent on the tissue structure, has been introduced 
in the assessment of liver fibrosis. The ADC value is lower in livers with heavier fibrosis 
because of the restriction of water diffusion in fibrotic tissue. Lewin et al. assessed the 
performance of DWMRI in 54 patients with chronic HCV infection with reference to several 
other non-invasive methods.In discriminating significant fibrosis, the area under the curve 
(AUC) values were 0.79 for DWMRI, 0.87 for transient elastography, 0.68 for the FibroTest, 
0.81 for aspartate aminotransferase to platelet ration index, 0.72 for the Forns index and 0.77 
for hyaluronate. DWMRI performed better in discriminating between patients staged F3–F4, 
when the AUC value increased to 0.92, the same as in transient elastography. But besides 
fibrosis, it seems that ADC values might also reflect the intensity of inflammation, necrosis 
and steatosis. However, DWMRI still benefits from the intrinsic advantages of MRI. (29) 
MR Spectroscopy 
Based on its anatomical location and increased metabolic demands, the liver is considered 
an ideal organ for MR spectroscopy investigation. 
In vivo MRspectroscopy is most commonly used to assess signals from hydrogen (1H) and 
phosphorus (31P). Although 1H-based MR spectroscopy allows for quantification of certain 
metabolites and lipids, 31P-based MR spectroscopy provides insights on processes including 
cell turnover and energy state based on substantial concentrations 
within hepatocytes. Within the spectrum of 31P compounds, 6 discrete signals have frequently 
been analyzed by MR spectroscopy in human subjects, including (1) phosphomonoesters 
(PME), (2) inorganic phosphate, (3)phosphodiesters (PDE), (4) adenosine triphosphate (ATP), 
alpha-ATP, and beta-ATP. The chemical precursors phosphocholine, phosphoethanolamnine, 
adenosine monophosphate, and glycolytic intermediates,such as glucose-6-phosphate 
contribute to the PME peak. Glycerophosphorylcholine, glycerophosphorylethanolamine and 
mobile phospholipids from the endoplasmic reticulum are the main components of the PDE 
peak. Both PME and PDE appear to provide information on cellular degradation.The 
methodology used for performing MR spectroscopy has varied over time and between studies. 
MR spectroscopy of the liver is performed using a whole body MRI system at field strengths of 
1.5 Tesla (T) or higher. 
After a standard MR imaging for localization, special MR pulse sequences are applied to 
generate spectroscopic data within the appropriate anatomical location and volume (defined 
by voxels) of interest. As with diffusion-weighted imaging, an examination will take 45 to 60 
minutes. 
The spectral analysis of data requires processing to reduce noise and perform analysis. 
Metabolite concentrations can be expressed in absolute or relative terms. In general, the 
peak area of a metabolite signal is directly related to its concentration. Because the absolute 
quantitation of metabolites is difficult to achieve in vivo, many studies have used metabolite 
ratios for assessing spectral profiles.Peak areas in a spectrum are referenced to standards for 
correlation with MR signal intensities. An internal standard such as adenosine triphosphate 
(ATP) can be used, given its natural occurrence in tissue. 
MR spectroscopy is recomended for investigation of diffuse liver disease, such as chronic 
hepatitis, steatosis non alcoholic fatty liver disease, for quantifying liver fat.There are also 
studies about the use of liver MR spectoroscopy for tumor assessment.The principal 
metabolite that has been targeted in focal liver disease is choline. Choline is elevated in 
tumors,because Choline is cell membrane compoment and increased cell turnover is 
associated with malignancy 
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Fig. 4.  
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(A) MR elastography of the liver in a healthy volunteer and a patient with cirrhosis. The 
middle column of images shows wave image data in the liver and spleen, superimposed 
on the corresponding anatomical images. The resulting elastograms are shown in the far 
right column. Elastograms show a higher mean stiffness of the fibrotic liver compared 
with the normal liver (12.1 ± 1.2 kPa versus 1.8 ± 0.3 kPa, respectively). (Adapted from Yin 
M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, Rossman PJ, et al. Assessment of 
hepatic fibrosis with magnetic resonance elastography. Clin Gastro Hepatol 2007. In 
press).  
(B) MR elastography of the liver in patients with obesity and ascites. The top row 
demonstrates a patient with obesity (BMI = 36) and stage 2 fibrosis on liver biopsy with a 
mean liver stiffness of 3.2 ± 0.8 kPa. The bottom row illustrates a patient with ascites. 
Excellent shear wave illumination of the liver was obtained, and the mean liver stiffness was 
11.3 ± 2.8 kPa. (Adapted from Yin M, Talwalkar JA, Glaser KJ, Manduca A, Grimm RC, 
Rossman PJ, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. 
Clin Gastro Hepatol 2007;5:1207-1213.e2.)  
MR elastography(MRE) 
is used for evaluation of the degree of liver fibrosis. The technic use is simile to that used in 
ultrasound elastography in that it uses a vibrafon device to induce a shear wave in the 
liver.The wave is detected by a modified magnetic resonance paging machine, and a color –
coded image is generated that depicts the wave velocity,and hence stiffness,throughout the 
organ. MRE demonstrated that patients with hepatic fibrosis have higher liver stiffness 
measurements than healththy volunters and that those with mild fibrosis were also able to 
be differentiated form those with moderate to advanced fibrosis,with mean hepatic shear 
elasticity being 2,24±0,23kPa in patiens with F0-F1 fibrosis, 2,56 ±0,24 kPa with F2-F3 fibrosis 
and 4,68 ±1,61 kPa in patiens with F4 fibrosis. MRE was found to have a higher technical 
succes rate than US elastography. 
Computed tomography 
CT imaging of liver provides specific method of noninvasive diagnosis of diffuse liver 
disease and also focal lesions of liver.Hepatic steatosis can be definied with a 76 % 
predictive value. Density of liver in steatosis is lower than density of intrahepatal vessels.CT 
imaging does not provide any information on the stage of fibrosis.CT imaging helps in 
diagnosis of cirrhosis according the nodular,irregular margin of liver.Pathological 
accumulation of iron increases density of liver parenchyma, but accumulation of copper 
does not change the density. 
Single photon emission computed tomography(SPECT) 
SPECT was tested in HIV-HCV co-infected patients,also in cirrhotic patients, in an effort to 
correlate histological severity of liver fibrosis with SPECT results.Cirrhotic patients showed 
a signifiant decrease of total liver uptake and a signifiant increase in total spleen 
uptake.Spleen volume was best at detecting liver cirrhosis, but total liver uptake correlated 
better with chronic liver disease severity. 
4. Breath tests 
There are several 13C breath tests for non-invasive investigation of hepatocellular function. 
13 C-methacetin breath test (MBT) is essentially a microsomal liver function test. The patient 
ingest 75g 13C-methacetin dissolved in 200 ml water. Breath samples are collected at 
baseline and 15 min after ingestion of substrate. During the test period,the patient is in rest 
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and fasts to avoid influences due to variations in CO2 production and food intake. 13C-
methacetin is rapidly metabolised by healthy liver cells into acetaminophen and by a single 
dealkylation, and the increase of CO in breath samples can be quantified by isotope ratio 
mass spectrometry or nondispersive isotope-selective infrared spectroscopy. The 13 C-
methacetin –breath test is more expensive than biochemical markers,but is also widely 
available.The breath samples can be sent to specialized centres or can be directly analysed as 
bedside test by nondispersive isotope-selective infrared spectrometers. The 13 C methacetin-
breath test is more practicable than other 13 C based liver function tests because it can be 
performed as a simple two-point measurements as known from the 13C urea breath test. 
The rapid metabolism of methacetin allows a short sampling interval for the breath 
test.Methacetin undergoes a high hepatic extraction rate,which makes the methacetin breath 
test susceptible to variations in hepatic blood flow. (27)  
13C methacetin-breath tests measure the functional metabolit capacity of residual hepatic 
cells and indirectly reflex how many hepatic cells are already lost .MBT has high sensitivity 
(93,5-95 %) and specificity (95-96,7%) for identifying cirrhotic patients, but can not differ 
patiens with early fibrosis and advanced fibrosis as determined by liver biopsy. 
Another breath test is the 13C-aminopyrine breath test (ABT), where the aminopyrine is 
another substrate for labelling with the 13C isotope, much like the MBT.  
5. Conclusion 
Liver biopsy is curerrently the most beneficial method in diagnostic of liver dieases.Non-
invasive methods of assessment of liver fibrosis,cirrhosis, steatosis are not able to replace 
liver biopsy because of their limitations.Increasing application of serum tests, imaging 
methods and breath tests is based on their advantages as absence of pain,of risk of 
complications, easy repeatability.  
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